• 1
    Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 185565.
  • 2
    De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 293847.
  • 3
    Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 234351.
  • 4
    Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 208491.
  • 5
    Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol 2006; 24: 394400.
  • 6
    Wilson RH, Lehky T, Thomas RR et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 176774.
  • 7
    Extra JM, Marty M, Brienza S et al. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998; 25: 1322.
  • 8
    Chang PM, Tzeng CH, Chen PM et al. ERCC1 codon 118 C[RIGHTWARDS ARROW]T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2009; 100: 27883.
  • 9
    Lai JI, Tzeng CH, Chen PM et al. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 2009; 100: 12616.
  • 10
    Board PG, Baker RT, Chelvanayagam G et al. A novel class of glutathione transferases in a range of species from plants to humans. Biochem J 1997; 328: 92935.
  • 11
    Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998; 19: 27580.
  • 12
    Stoehlmacher J, Park DJ, Zhang W et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004; 91: 34454.
  • 13
    Stoehlmacher J, Park DJ, Zhang W et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 93642.
  • 14
    Sato K. Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res 1989; 52: 20555.
  • 15
    Mir O, Alexandre J, Tran A et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009; 20: 73640.
  • 16
    Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12: 30506.
  • 17
    Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18: 6414.
  • 18
    Chang A, Parikh P, Thongprasert S et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1: 84755.
  • 19
    Liu CY, Chen PM, Chiou TJ et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 193240.
  • 20
    Marsh S, Collie-Duguid ES, Li T et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999; 58: 3102.
  • 21
    Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5’-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 1917.
  • 22
    Chenevix-Trench G, Young J, Coggan M, Board P. (1995) Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age at onset. Carcinogenesis 1995; 16: 16557.
  • 23
    Lee WH, Morton RA, Epstein JL et al. Cytidine methylation of regulatory sequences near the Pi class glutathione S transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 117337.
  • 24
    Ates NA, Tamer L, Ates C et al. Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet 2005; 43: 14963.
  • 25
    Grolleau F, Gamelin L, Boisdron-Celle M et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 22937.
  • 26
    Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007; 25: 124754.
  • 27
    Kweekel DM, Gelderblom H, Antonini NF et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer 2009; 45: 5728.
  • 28
    Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T. Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 1999; 31: 54958.
  • 29
    Hayes JD, Wolf CR, Townsend DM et al. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 736977.
  • 30
    Nishimura T, Newkirk K, Sessions RB et al. Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996; 2: 185965.
  • 31
    Sun N, Sun X, Chen B et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009 Jul 1. [Epub ahead of print]
  • 32
    Voso MT, Hohaus S, Guidi F et al. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. Leukemia 2008; 22: 168591.
  • 33
    Goekkurt E, Hoehn S, Wolschke C et al. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006; 94: 2816.
  • 34
    Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer. Breast Cancer Res Treat 2008; 111: 93101.
  • 35
    Kweekel DM, Koopman M, Antonini NF et al. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer 2008; 99: 131621.